How Similar Are Biosimilars? A Look Into the Future With Biosimilars in Multiple Sclerosis
Advanced practice providersdiscuss the who, what, where of biosimilars, a potential role of biosimilars in MS, and clinical data on biosimilars currently in development for MS. They provide insights into how to incorporate biosimilars into MS clinical practice.
EP. 2: Comparison of Biosimilar Products and Reference Products
Clinical experts discuss differences and similarities between biosimilars and reference products.
EP. 3: Approval Process for Biosimilars
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.
EP. 4: Immunogenicity of Biosimilars
Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.
EP. 5: Cost Savings with Biosimilars and Use in Multiple Sclerosis
Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.
EP. 6: Natalizumab Biosimilar in Development in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.
EP. 7: Comparison of AFFIRM (Reference Natalizumab) and Antelope (Biosimilar Natalizumab) Trials
Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.
EP. 8: Access to and Challenges to Biosimilar use in Clinical Practice
John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.
EP. 9: Implementing Biosimilars in Clinical Practice
Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.
EP. 10: Biosimilar Discussion With Patients and Biosimilar Resources
Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.
EP. 11: Concluding Thoughts on Biosimilars in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
